Marker Therapeutics Company

Marker Therapeutics is a clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform.
Technology: CAR-T therapy
Industry: Public
Headquarters: Minneapolis, Minnesota, United States
Founded Date: 1992-01-01
Employees Number: 51-100
Funding Status: IPO
Investors Number: 3
Total Funding: 96600000
Last Funding Date: 2022-12-13
Last Funding Type: Post-IPO Equity

Visit Website
Register and Claim Ownership